Boehringer Ingelheim Venture Fund invests precision antimicrobials
Boehringer Ingelheim Venture Fund invests in the development of precision antimicrobials
Search
Partnership for new liver disease treatments with Ribo
Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseases
Boehringer Ingelheim acquires Nerio Therapeutics
Today marks a significant step for Boehringer Ingelheim’s immuno-oncology pipeline by adding an innovative preclinical program with the acquisition of Nerio Therapeutics
Cooperation with Google Quantum AI
Boehringer Ingelheim collaborates with the Broad Institute
Boehringer Ingelheim and researchers at the Broad Institute of MIT and Harvard are collaborating to tackle the unmet needs of people living with mental health conditions.
Sant Cugat del Vallès
The site in Sant Cugat del Vallès focuses on pharmaceutical production and is one of the production sites of the RESPIMAT®.
cat dog flea allergy dermatitis
Find out how you can identify and treat flea allergy dermatitis, one of the most common illnesses associated with a flea infestation.
COVID-19 Material donations in Germany
FDA-CRL-T1D
US FDA issues complete response letter for treatment of adults with type 1 diabetes
Phase II clinical trial weight loss results
Data shows nearly 19% weight loss in people with overweight or obesity in Phase II trial with survodutide (BI 456906)
opening-solids-launch-fabrik
Boehringer Ingelheim today opened a tablet factory at Ingelheim in the presence of the State Premier of Rhineland-Palatinate, Malu Dreyer.
First Translational Medicine Award awarded
The Award recognizes the research that has the highest translational potential
Pride Month 2023: Why belonging matters – to all of us
LGBTIQ+ community members and their allies share how we can create a welcoming and inclusive culture where everyone feels heard, accepted and appreciated.
Boehringer expands cancer research at Vienna site
Boehringer Ingelheim expands cancer research at its Vienna site
Jean-Michel Boers Appointed to PhRMA Board of Directors
Jean-Michel Boers Appointed to PhRMA Board of Directors
Animal Health Collaboration with Novozymes
Boehringer Ingelheim Animal Health and Novozymes today announced a strategic collaboration to develop and commercialize probiotics for global poultry production. Boehringer Ingelheim will market and distribute Novozymes’ FloraMax® probiotic product f
Acquisition expands research in cancer immunology
Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.
Redefining mental health to enable people to thrive
At Boehringer Ingelheim, we aim to develop targeted treatment approaches that address specific symptoms in people living with mental illness.
Rethinking mental health care
Outdated perceptions and practices fuelling mental health crisis, new Economist Impact study reveals
Phase 3 studies survodutide obesity and overweight
Phase 3 studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
Retinal Health Research
Our research is targeting key mechanisms in the pathogenesis of retinal diseases – vascular dysfunction, neuronal dysfunction and neuronal inflammation.
Distributing medicine globally with pharmaceutical logistics
From Germany to Australia, here’s what it takes from operations and logistics to ensure patients get their medicine on time, every time.
ArisGlobal acquires Boehringer Ingelheim technology
Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal
Equestrian sports horse health awareness Alex Hua Tian
Together with Olympian trailblazer and eventer Alex Hua Tian, we educate about equine health in China.
Digital innovation: Our digital pipeline is only growing
BRASS, a software advancing patient safety and developed fully in-house, has been sold. This is proof: our digital innovations are in demand.